Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma

  • Study type:

    Interventional What is this?

    Describes the nature of a clinical study. Types include:

    • Observational study — observes people and measures outcomes without affecting results.
    • Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
    • Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
  • Study phase:

    III What is this?

    During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Study IDs

  • Site IRB:

    • Rochester, Minnesota: 1617-04
  • NCT ID:

    NCT00085735
  • Sponsor Protocol Number:

    ACNS0331

About this study

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy, such as vincristine, cisplatin, lomustine, and cyclophosphamide, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving radiation therapy with chemotherapy after surgery may kill any remaining tumor cells. It is not yet known whether standard-dose radiation therapy combined with chemotherapy after surgery is more effective than reduced-dose craniospinal (head and spine) radiation therapy plus either posterior fossa (back of the brain) boost or tumor bed (site of the tumor) boost radiation therapy combined with chemotherapy in treating medulloblastoma.

PURPOSE: This randomized phase III trial is studying standard-dose radiation therapy to see how well it works compared to reduced-dose craniospinal radiation therapy AND posterior fossa boost radiation therapy to see how well it works compared to tumor bed boost radiation therapy when given together with chemotherapy in treating young patients who have undergone surgery for newly diagnosed standard-risk medulloblastoma.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

See eligibility criteria

Disease Characteristics:

  • Histologically confirmed medulloblastoma located in the posterior fossa
    • Standard-risk disease
  • Minimal volume, non-disseminated disease, defined by the following:
    • Residual tumor ≤ 1.5 cm^2 confirmed by MRI with contrast imaging within 21 days after surgery
    • No metastatic disease in the head, spine, or cerebrospinal fluid (CSF) confirmed by both of the following:
      • Enhanced MRI of the spine within 5 days before surgery OR within 28 days after surgery
      • Negative cytological examination of CSF after surgery, but before study enrollment
    • Brain stem involvement allowed

Patient Characteristics:

  • Age 3 to 21 at diagnosis
  • Performance status
    • Karnofsky 50-100% (> 16 years of age) OR
    • Lansky 30-100% (≤ 16 years of age)
  • Hematopoietic
    • Absolute neutrophil count > 1,500/mm^3
    • Platelet count > 100,000/mm^3 (transfusion independent)
    • Hemoglobin > 10 g/dL (transfusions allowed)
  • Hepatic
    • Bilirubin < 1.5 times upper limit of normal (ULN)
    • AST or ALT < 1.5 times ULN
  • Renal
    • Creatinine clearance OR radioisotope glomerular filtration rate ≥ 70 mL/min
  • Other
    • Not pregnant or nursing
    • Negative pregnancy test
    • Fertile patients must use effective contraception

Prior Concurrent Therapy:

  • Chemotherapy
    • No prior chemotherapy
  • Endocrine therapy
    • Prior corticosteroids allowed
  • Radiotherapy
    • No prior radiotherapy

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Amulya NageswaraRao, MBBS

Contact us for the latest status

Cancer Center Clinical Trials Referral Office

855-776-0015